These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 408654)

  • 21. The price of innovation: new estimates of drug development costs.
    DiMasi JA; Hansen RW; Grabowski HG
    J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Second medical conference in the Berufsförderungswerk Wildbad, on March 2-4, 1973 (author's transl)].
    Münz D
    Rehabilitation (Stuttg); 1973 Aug; 12(3):182-5. PubMed ID: 4274522
    [No Abstract]   [Full Text] [Related]  

  • 23. Outpatient cancer drug costs: changes, drivers, and the future.
    Halbert RJ; Zaher C; Wade S; Malin J; Lawless GD; Dubois RW
    Cancer; 2002 Feb; 94(4):1142-50. PubMed ID: 11920485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [In support of drug transparency].
    Platzer E
    MMW Munch Med Wochenschr; 1979 May; 121(19):suppl 25-6. PubMed ID: 112383
    [No Abstract]   [Full Text] [Related]  

  • 25. Marketing Medicaid drugs: an analysis of cost factors.
    Simmons SA; Payne BC; Smith MC
    J Health Care Mark; 1986 Sep; 6(3):29-36. PubMed ID: 10301037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Drug monitoring in psychiatry (author's transl)].
    Rüther E; Benkert O; Eckmann F; Eckmann I; Grohmann R; Helmchen H; Hippius H; Müller-Oerlinghausen B; Poser W; Schmidt L; Stille G; Strauss A; Uberla K
    Arzneimittelforschung; 1980; 30(8):1181-3. PubMed ID: 7192131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Health insurance discount contracts: problems and risks for the general practitioner in the medical care of patients with chronic illness].
    Leutgeb R; Mahler C; Laux G; Weschnetz A; Szecsenyi J
    Dtsch Med Wochenschr; 2009 Jan; 134(5):181-6. PubMed ID: 19180404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Methods for an economic analysis of health care (author's transl)].
    Henke KD
    Offentl Gesundheitswes; 1978 Dec; 40(12):789-94. PubMed ID: 152882
    [No Abstract]   [Full Text] [Related]  

  • 29. Adverse drug reactions: a review for healthcare practitioners.
    Young LR; Wurtzbacher JD; Blankenship CS
    Am J Manag Care; 1997 Dec; 3(12):1884-906; quiz 1909-10. PubMed ID: 10178476
    [No Abstract]   [Full Text] [Related]  

  • 30. [Attempted suicide in Lübeck 1947-1968, data and tendencies (author's transl)].
    Böhme K; Ahrens M; Dittsbrenner M; Hirsekorn K; Willems W
    Fortschr Neurol Psychiatr Grenzgeb; 1976 Oct; 44(10):559-69. PubMed ID: 1049557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of the National Institute for Health and Clinical Excellence's technology appraisals on prescribing and net ingredient costs of drugs in the National Health Service in England.
    Dietrich ES
    Int J Technol Assess Health Care; 2009 Jul; 25(3):262-71. PubMed ID: 19619344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.
    Michaud K; Messer J; Choi HK; Wolfe F
    Arthritis Rheum; 2003 Oct; 48(10):2750-62. PubMed ID: 14558079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent trends in drug prescribing rates and costs in New Zealand.
    Malcolm LA; Mehl A
    N Z Med J; 1988 May; 101(845):233-6. PubMed ID: 3368132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Why drug prices are high in sub-Saharan Africa. Analysis of price structure: the case of Senegal].
    Guimier JM; Candau D; Garenne M; Teulières L
    Sante; 2005; 15(1):41-52. PubMed ID: 15919632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Explosion of cost in the public health sector--the chances and tasks of the public health services (author's transl)].
    Hoffmeister H
    Offentl Gesundheitswes; 1978 Jul; 40(7):408-17. PubMed ID: 150563
    [No Abstract]   [Full Text] [Related]  

  • 37. [The surgeon as a cost factor. Cost analysis exemplified by surgical treatment of rectal carcinoma].
    Meyer T; Merkel S; Pfaffenberger M; Hohenberger W
    Chirurg; 2002 Feb; 73(2):167-73. PubMed ID: 11974481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Not by price alone: research, new drugs best route to cost control.
    Markoe F
    Hosp Formul; 1978 May; 13(5):384-5, 389. PubMed ID: 10307638
    [No Abstract]   [Full Text] [Related]  

  • 39. [Letter: Determination of adverse effects of drugs].
    Brück D
    Med Klin; 1974 Nov; 69(48):2007. PubMed ID: 4453296
    [No Abstract]   [Full Text] [Related]  

  • 40. [Costs of the treatment of hyperglycemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: results of the German CoDiM study].
    von Ferber L; Köster I; Hauner H
    Med Klin (Munich); 2006 May; 101(5):384-93. PubMed ID: 16685485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.